SomnusNooze e-newsletter
News, stories and updates from the world of sleep
SomnusNooze Month: December 2015
HF Welcomes Several New Board Members
The Board of Directors of the Hypersomnia Foundation is pleased to introduce three new board members to the Board of Directors, Scientific Advisory Board, and Medical Advisory Board. Diane Powell and to announce the appointment of two new members of the... read >
EMA Recommends Approval of Pitolisant for the Treatment of Narcolepsy
On November 20, 2015, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that Bioprojet Pharma's drug pitolisant (Wakix) be approved for the treatment of narcolepsy with or without cataplexy. In... read >
Crash Course: Public School Accommodations for Children with Hypersomnia – Part 4
This is the last in a series of four articles explaining how to navigate the public school system for accommodations under a 504 plan. You can read the other parts here: part 1, part 2, and part 3. By Kate Pece, MEd A K-12 Idiopathic Hypersomnia Fact... read >
The First Multi-Site Clinical Trial for IH and Type 2 Narcolepsy in the US Is Underway
ARISE 201 is the first double-blind, placebo-controlled, crossover, multicenter study of a drug (BTD-001) for the treatment of idiopathic hypersomnia (IH) and type 2 narcolepsy (T2N) in adults. More than 20 study sites throughout the United States are... read >